Arcutis Biotherapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, as per a letter dated February 6, 2024. The company seeks to have the Registration Statement, with the number 333-276794, become effective by 4:00 p.m. Washington, D.C. time on February 8, 2024, or as soon as possible thereafter. This request was made under Rule 461 of the Securities Act of 1933, as amended. Arcutis has indicated that their counsel, Latham & Watkins LLP, may request a different effective time by phone. The company has asked the SEC to confirm the effectiveness of the Registration Statement orally with their counsel following its declaration.

Arcutis Biotherapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, as per a letter dated February 6, 2024. The company seeks to have the Registration Statement, with the number 333-276794, become effective by 4:00 p.m. Washington, D.C. time on February 8, 2024, or as soon as possible thereafter. This request was made under Rule 461 of the Securities Act of 1933, as amended. Arcutis has indicated that their counsel, Latham & Watkins LLP, may request a different effective time by phone. The company has asked the SEC to confirm the effectiveness of the Registration Statement orally with their counsel following its declaration.